Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
March 24 2022 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that Brian M.
Culley, the Company’s Chief Executive Officer, will be presenting
at the 2022 Virtual Growth Conference, presented by Maxim Group LLC
and hosted by M-Vest. Mr. Culley will be participating in an
“Ophthalmology Panel” hosted by Jason McCarthy, Ph.D., Senior
Managing Director, Biotechnology, on March 28th, 2022 at 10am ET /
7am PT. Mr. Culley will also provide a corporate overview which
will be available to investors on demand, starting on Monday March
28th, 2022.
The live panel and on-demand presentation will be available to
registered users directly through the M-Vest platform:
https://m-vest.com/events/2022-virtual-growth-conference.
Registration is required for conference participation. An archived
webcast of the corporate presentation will also be available on the
Events and Presentations page of the Lineage website. Additional
videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include four allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, which is now being developed under a worldwide
collaboration with Roche and Genentech, a member of the Roche
Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in
Phase 1/2a development for the treatment of acute spinal cord
injuries; (iii) VAC2, a dendritic cell therapy produced from
Lineage’s VAC technology platform for immuno-oncology and
infectious disease, currently in Phase 1 clinical development for
the treatment of non-small cell lung cancer and (iv) ANP1, an
auditory neuronal progenitor cell therapy for the potential
treatment of auditory neuropathy. For more information, please
visit www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220324005234/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Mike Biega (Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024